AbbVie (NYSE: ABBV) reported Q4 EPS of $3.31, $0.03 better than the analyst estimate of $3.28. Revenue for the quarter came in at $14.89 billion versus the consensus estimate of $14.95 billion.

GUIDANCE:

AbbVie sees FY2022 EPS of $14.00-$14.20, versus the consensus of $13.99.

• AbbVie is issuing its GAAP diluted EPS guidance for the full-year 2022 of $9.26 to $9.46. AbbVie expects to deliver adjusted diluted EPS for the full-year 2022 of $14.00 to $14.20. The company's 2022 adjusted diluted EPS guidance excludes $4.74 per share of intangible asset amortization expense, non-cash charges for contingent consideration adjustments and other specified items.

For earnings history and earnings-related data on AbbVie (ABBV) click here.